Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brett King

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Journal of the American Academy of Dermatology|July 25, 2024
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)Brett King, Maryanne M Senna, Natasha A Mesinkovska, et al.
The British Journal of Dermatology|February 10, 2023
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trialsBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.
The British Journal of Dermatology|March 29, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trialBrett King, Benjamin Ehst, Peter Foley, et al.
American Journal of Clinical Dermatology|January 23, 2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
Experimental Dermatology|September 20, 2024
Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analysesElena Peeva, Yuji Yamaguchi, Zhan Ye, et al.
The New England Journal of Medicine|March 25, 2022
Two Phase 3 Trials of Baricitinib for Alopecia AreataBrett King, Manabu Ohyama, Ohsang Kwon, et al.
Journal of the American Academy of Dermatology|October 18, 2024
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trialMelissa Piliang, Charles Lynde, Brett King, et al.
Immunotherapy|July 5, 2023
A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areataBrett King, Xingqi Zhang, Walter Gubelin Harcha, et al.
Lancet (London, England)|April 16, 2023
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trialBrett King, Xingqi Zhang, Walter Gubelin Harcha, et al.
The Journal of Dermatology|September 27, 2024
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalisNatasha Mesinkovska, Brett King, Xingqi Zhang, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Journal of the American Academy of Dermatology|July 25, 2024
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)Brett King, Maryanne M Senna, Natasha A Mesinkovska, et al.
The British Journal of Dermatology|February 10, 2023
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trialsBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.
The British Journal of Dermatology|March 29, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trialBrett King, Benjamin Ehst, Peter Foley, et al.
American Journal of Clinical Dermatology|January 23, 2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
Experimental Dermatology|September 20, 2024
Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analysesElena Peeva, Yuji Yamaguchi, Zhan Ye, et al.
The New England Journal of Medicine|March 25, 2022
Two Phase 3 Trials of Baricitinib for Alopecia AreataBrett King, Manabu Ohyama, Ohsang Kwon, et al.
Journal of the American Academy of Dermatology|October 18, 2024
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trialMelissa Piliang, Charles Lynde, Brett King, et al.
Immunotherapy|July 5, 2023
A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areataBrett King, Xingqi Zhang, Walter Gubelin Harcha, et al.
Lancet (London, England)|April 16, 2023
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trialBrett King, Xingqi Zhang, Walter Gubelin Harcha, et al.
The Journal of Dermatology|September 27, 2024
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalisNatasha Mesinkovska, Brett King, Xingqi Zhang, et al.
Pageof 8